Amlodipine Besylate/Rosuvastatin Calcium/Ezetimibe

苯磺酸氨氯地平/瑞舒伐他汀钙/依折麦布

Report date: 2024/12/10 09:15:52

Base Information

Drug NameAmlodipine Besylate/Rosuvastatin Calcium/Ezetimibe
Drug Alias NameAmlorzet
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel blockersHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitors +[4] 
TargetsVoltage-gated calcium channelHMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsDyslipidemiasHypertension
Global Approved IndicationsDyslipidemiasHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2024/11/27
Country/TerritorySouth Korea
CombinationsYes Rosuvastatin CalciumEzetimibeAmlodipine Besylate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Pharm Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Pharm Inc
Inactive CompaniesN/A
Active IndicationsDyslipidemiasHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A